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Heart failure is one the leading cause of death worldwide and has reached 
epidemic proportions in most industrialized nations. Despite major 
improvements in the treatment and management of the disease, the prognosis 
for patients with heart failure remains poor with approximately only half of 
patients surviving for five years or longer after diagnosis. The poor prognosis 
of HF patients is in part due to irreparable damage to cardiac tissue and 
concomitant maladaptive changes associated with the disease. Cell-based 
therapies may have the potential to transform the treatment and prognosis of 
HF through regeneration or repair of damaged cardiac tissue. Accordingly, 
numerous phase I and II randomized clinical trials have tested the clinical 
benefits of cell transplant, mostly autologous bone marrow-derived 
mononuclear cells, in patients with heart failure, ischaemic heat disease and 
acute myocardial infarction. Although many of these trials were relatively 
small, meta-analyses of cell-based therapies have attempted to apply rigorous 
statistical methodology to assess the potential clinical benefits of the 
intervention. As a prelude to larger phase III trials, meta-analyses therefore 
remain the obvious means of evaluating the available clinical evidence. Here, 
we review the different meta-analyses of randomized clinical trials that 
evaluate the safety and potential beneficial effect of cell therapies in heart 
failure and acute myocardial infarction spanning nearly two decades since the 




Cardiovascular disease (CVD), of which ischaemic heart disease (IHD) is a major 
component, is the leading cause of mortality accounting for approximately one third 
of deaths worldwide 1. Although the death rate associated with IHD has gradually 
declined over the last fifty years the incidence and prevalence of heart failure (HF) is 
on the increase and has become almost a pandemic. Paradoxically, the Center for 
Disease Control and Prevention have recently reported an increase in the age-
adjusted rate for HF-related mortality. 2 The majority of treatment options in HF are 
palliative or aimed at slowing down disease progression (e.g. the prevention of 
cardiomyocyte loss or treatment of symptoms). In parallel to the increased incidence 
of HF, the use of new therapies such as coronary interventions, resynchronization 
therapy and the implantation of ventricular assist devices has also risen. As a 
consequence, hospitalisation due to HF has become more frequent, imposing a real 
economic burden on health care providers across the world. Therefore, there is an 
unmet clinical need to improve heart performance of patients who suffer IHD and HF 
and restore heart function.  
 
Unlike many other tissues, heart muscle has a limited capacity to adequately repair 
itself after injury leading to progressive maladaptive remodelling and left ventricular 
dysfunction. Given the limited propensity for the heart to repair itself following injury, 
numerous strategies to repair or regenerate the damaged tissue have been proposed 
and tested in pre-clinical models and small to medium sized phase I and phase II 
clinical trials. 3, 4 One of the most promising strategies to repair or regenerate the 
damaged myocardium involves the use of cell-based therapies. Although several 
different experimental cell types have been tested in pre-clinical (animal) models and 
small scale clinical trials, the most commonly used cells are bone marrow-derived 
stem/progenitor cells (BMSCs) or bone marrow mononuclear cells (BMMNCs), 
derived from the patient’s own bone marrow and are therefore an autologous cell 
transplant. Bone marrow is a heterogeneous tissue containing multiple cell 
populations of which approximately 1% are stem/progenitor cell populations of 
hematopoietic origin, multipotent mesenchymal stromal cells (MSCs) and endothelial 
progenitors. Unfractionated BMMNCs have been extensively used in clinical trials 
with the aim of repairing damaged heart tissue. Enriched populations of bone 
marrow-derived stem or progenitor cells can be isolated from BMMNCs using 
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antibodies against different cell surface antigens such as CD34 and CD133, through 
adaption to culture or by mobilisation into the peripheral blood stream following 
stimulation with cytokines such as G-CSF (Granulocyte-colony stimulating factor). In 
addition to BMSCs, other cell types  such as skeletal myoblasts, adipose tissue-
derived stem/progenitor cells, endothelial progenitors and cardiac progenitor cells 
have been tested in animal models and small clinical trials. 3  
 
All randomized control trials (RCTs) included in the meta-analyses described herein 
include a control arm(s) for each of the constituent trials. The control arm or placebo 
for many RCTs is often heterogeneous (no cells, unconditioned media or vehicle, 
mock injection etc.). Arguably the most appropriate control for these studies is to use 
irradiated bone marrow stem cells that are unable to replicate.  Although not included 
in the meta-analyses described herein, Wollert and colleagues have recently 
published a RCT for myocardial infarction where g-irradiated stems cells were 
included in one of the control arms of the trial. 5 Importantly, this trial found that bone 
marrow stem cell therapy had no significant effect on LVEF improvement in patients 
treated with viable bone marrow stem cells compared to the control population that 
received irradiated cells. 
 
The focus of this review is on the meta-analyses of RCTs for cell therapy in heart 
failure (HF) and acute myocardial infarction (AMI) using ostensibly autologous BMSC 
transplants. 
 
Meta-analysis in preclinical models 
Pre-clinical studies carried out in animal models present a unique opportunity to 
conduct homogenous trials, e.g. cell-treatment in a pre-specified time, similar animal 
strain and species, without confounding clinical factors. Recently, meta-analyses of a 
large number of pre-clinical studies of cell-based therapy in animal models of IHD 
have been published. 6-9 Frequently, clinical outcomes (e.g. mortality) are not 
relevant in these studies, mostly due to the limited number of animals included in the 
studies and short follow-up times. However, efficacy parameters could be 
comparable to human clinical trials, especially in large animals where LV function 
and trial outcomes are measured using similar imaging modalities (e.g. magnetic 
resonance imaging or MRI). A meta-analysis of cell treatment studies in a mouse 
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model of myocardial ischemia, including only studies using cardiac MRI as functional 
analytic method of LV performance (21 randomized studies with a total of 583 mice), 
resulted in a significant improvement in LVEF of 8.59% as compared to the placebo-
treated animals. 7 Likewise, two meta-analyses of 52 and 82 large animal trials 
(pooling data from 888 and 1415 animals, respectively with iatrogenic ischemic heart 
disease reported an 8.3% LVEF benefit of cell-based therapy in contrast to control 
animals. 6, 8 Furthermore, a meta-analysis of cardiac progenitor cell (c-kit+, Sca-1+, 
cardiosphere and cardiosphere-derived cells) therapy studies in AMI (including 80 
studies with 1970 rodents and large animals) reported a mean 10.7% LVEF increase 
in the cell-treated group compared to the control group. 9 Interestingly, cardiac 
progenitor cell therapy led to a significantly higher effect in rodents than in large 
animals (increase of LVEF of 11.7% and 5.2% in small and large animals, 
respectively). The increase in LVEF following cell transplantation in large animals 
closely relates to the 5-7% improvement in LVEF observed in human clinical trials. 
Although Zwetsloot et al., found that the large animal studies were superior in quality 
to their small animal counterparts, showed less evidence of publication and attrition 
biases, the differences in LVEF improvement between large and small animal pre-
clinical models are not fully understood. 9 While these unresolved differences may 
have a methodological or biological origin, it is noteworthy that the smaller effects on 
LVEF improvement in large animal studies are more closely reminiscent of the trial 
data derived from human subjects and as such may indicate that large animal are the 
more appropriate preclinical model for stem cell therapy for cardiac repair. In order to 
standardize animal studies and to avoid or reduce heterogeneity, and to draw more 
meaningful conclusions, the NHLBI-sponsored CAESAR consortium and the Working 
Group on Cellular Biology of the Heart of the European Society of Cardiology have 
suggested, that pre-clinical studies should also be performed as multi-center 
randomized blinded studies, similar to human clinical trials. 10, 11  
 
Meta-analyses of cell therapies in heart failure 
Several small or medium-sized Phase I and II cell-based therapy studies have been 
conducted in HF patients. Currently, approximately 2300 patients with ischemic HF or 
chronic ischemic heart disease have been treated with different types of cells, mostly 
with autologous BMMNCs in 45 randomized trials. Other cell types, such as bone 
marrow-derived MSC, adipose tissue MSC, bone-marrow and peripheral blood 
 7 
progenitor cells, cardiac progenitor cells (cardiospheres) or myoblasts were also 
used. HF patients with the characteristics of HFrEF (heart failure with reduced 
ejection fraction) can mostly be characterized by post-infarction ischemic 
cardiomyopathy with severe coronary artery disease. Therefore, intramyocardial 
delivery of cell, either by surgical or percutaneous intervention, seems to be the 
preferred route of delivery for the intervention. This is in contrast to patients with 
recent acute myocardial infarction (AMI) enrolled in cell therapy trials and who 
received cell treatment by intracoronary delivery.   
 
Since the average number of participants in trials are rarely over 50, most of the cell-
based therapy studies in HF patients are statistically underpowered. Due to the 
technical challenges of these trials, namely percutaneous or surgical intramyocardial 
cell delivery, patient enrolment in randomized trials is usually slow, commonly leading 
to premature study termination, and/or inconclusive trial results. Hence, systematic 
reviews and meta-analyses of cell-based regenerative therapies including larger 
numbers of patients are necessary to evaluate the clinical evidence of cell therapy 
interventions in this cohort of patients. Table 1 lists the characteristics and results of 
currently published meta-analyses that included randomized trials involving patients 
with signs of HF and aimed to assess the effect of cell-therapy on LVEF. 12-24 All trials 
included in these meta-analyses used autologous cells and no restriction was made 
with respect to the type of cells used. The summary table shows non-uniform patient 
populations, including also some studies with recent AMI or refractory angina. The 
majority of trials delivered the cells intramyocardially via percutaneous intervention. 
Understandably, therapeutic cell delivery requires coronary artery bypass surgery 
and injection of the cells into the non-revascularizable (hibernating) areas of the 
diseased myocardium. Furthermore, intracoronary cell infusion into selected arteries 
may not be sufficient in cases of multivessel disease or diffuse chronic ischemic 
myocardium. Most of the meta-analyses reported significant changes in left 
ventricular parameters (Table 2), namely left ventricular ejection fraction (LVEF), left 
ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume 
(LVESV). However, the clinical outcomes of these meta-analyses are inconclusive 
(Table 1) since only 5 of the 13 meta-analyses reported a significant reduction in the 
risk of mortality in favour of the cell treatment in HF patients. 19, 21-24 
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Apart from 2 meta-analyses (Cheng et al., 2013 and Fisher et al., 2016), all studies 
reported a significant increase in LVEF in cell-treated patients compared to the 
control groups. 18, 24 These discrepancies are potentially explained by differences in 
statistical power related to the sample size in each study. Cheng et al., included only 
5 RCTs in their meta-analysis and could therefore be under-powered to detect 
statistically significant changes in LVEF. Conversely, Fisher and colleague’s meta-
analysis included 1114 patients from 38 trials and would therefore have greater 
statistical power to detect an effect. It appears that with the inclusion of larger 
number of patients in the meta-analysis, the observed treatment effect on LVEF 
regresses to a point where the changes are no longer significant. Importantly, this 
finding is also observed in the largest meta-analyses for AMI. 25, 26 Although LVEF is 
one of the most commonly used surrogate and prognostic markers in HF and an 
outcome measure in cell therapy RCTs, differences in the techniques used to 
measure LVEF are a source of heterogeneity when evaluating different studies. 27 
Furthermore, the physiological and clinical significance of the small percentage 
changes in LVEF reported in most cell therapy RCTs has yet to be established.  
 
Based on several pitfalls of the publication-based meta-analyses, namely the high 
heterogeneity of the trials, different follow-up times, doubled publications and mixed 
patient population, an individual data (IPD)-based meta-analysis of HF cell-based 
therapy trials would be desirable, such as the ACCRUE (Meta-Analysis of Cell-based 
CaRdiac stUdiEs) study in AMI patients. 25 The IPD-based meta-analysis of 
percutaneous intramyocardial delivery of regenerative cells in patients with HF is 
currently under statistical analysis, and some preliminary results have already been 
presented (Gyongyosi, unpublished data). 
 
Meta-analysis of cell therapy trials in acute myocardial infarction 
As is the case with HF and IHD, several small or medium-sized phase I and II cell-
based therapy RCTs have been undertaken in patients with AMI. Currently, 
approximately 2700 patients have been included in meta-analyses of 41 RCTs of 
autologous cell therapy transplantation in AMI using predominantly BMSCs. It should 
be noted that many more AMI patients have been treated with cell therapies 
however, many RCTs and prospective uncontrolled studies do not meet the selection 
criteria for meta-analyses and were therefore excluded from further analysis. Patients 
 9 
who suffered AMI underwent revascularization, mostly percutaneous coronary 
intervention or PCI, and received cell treatment following revascularization. 
Participants recruited to these trials presented LV dysfunction even after PCI and 
therefore, the rationale was that LVEF and LV volumes could be improved by cell 
transplantation. Therefore, changes in LVEF and LV volumes were the primary 
outcome of these trials. Cells were delivered mostly by infusion into the infarct-
related coronary artery (intracoronary cell delivery). 
 
Table 3 summarizes meta-analyses of bone marrow derived cell therapies for AMI 
published in the last 11 years. The first meta-analysis of cell therapy trials for AMI 
published in 2006 that included 482 patients enrolled in 5 RCTs, found a significant 
(P = 0.04) increase in LVEF between baseline and follow-up in the treatment group 
compared to controls but, more importantly, showed no difference in LVEF between 
treatment groups at follow-up, on average 5 months later. 28 By contrast, the first 
large scale meta-analysis of cell therapy for AMI collating data on 811 patients from 
13 RCTs found a modest improvement in LVEF (2.99%), and a significantly reduced 
left ventricular end-systolic volume (LVESV) by 4.74 mL and myocardial lesion area 
by (3.51%) in patients treated with BMSCs compared to controls (Table 3). Subgroup 
analysis revealed that there was a statistically significant difference in LVEF in favour 
of BMSCs when cells were infused within 7 days following AMI and when the BMSC 
dose administered was higher than 108 cells. However, patients in the control group 
also showed a greater increase in LVEF if they were included into the trial within 7 
days post-AMI. 25 In addition, the authors reported anecdotal trends in favour of 
benefit for most clinical outcomes examined, although none were statistically 
significant. 
 
Meta-analysis of further trials incorporating increasing numbers of patients and 
longer follow-ups have produced largely similar results (Table 3), although their 
conclusions have been equivocal. Broadly speaking, these studies have reported 
modest but significant changes in LV function allied with no improvement in mortality 
in patients treated with cell therapies compared to the placebo arm of the trial. Larger 
meta-analyses such as those reported by Clifford et al., and Zimmet et al., found 
significant changes in LV function and LVEF (1.78%, Clifford et al.) measured using 
MRI, commonly regarded as the reference method for estimating LV volumes and 
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ejection fraction. 29, 30 Although the improvements in LVEF may be statistically 
significant it is unlikely that these small changes are clinically relevant. 
 
In addition to the clinical heterogeneity of these trials, early meta-analyses also 
observed statistical heterogeneity. Many of the larger meta-analyses in AMI have 
attempted to explain some of the heterogeneity associated with cell therapy for AMI, 
and have included subgroup analyses to examine the effects of different variables on 
LV function and clinical outcomes. For example, Delewi and colleagues found that 
intracoronary delivery of BMSCs led to a moderate improvement of LVEF and a 
reduction in recurrent AMI and readmission to hospital for heart failure, unstable 
angina or chest pain. Similarly, patients receiving intracoronary BMSCs within a 3 to 
7 day window post-AMI were found have improved LVEF and decreasing end 
systolic and end diastolic volumes compared to patients treated within 24h or beyond 
7 days after AMI suggesting that transplant timing may be a relevant source of 
heterogeneity in some meta-analyses. 31 A recent meta-analysis focussing on cell 
therapy trials in both AMI and IHD collated data from 48 RCTs that enrolled a total of 
2602 patients (n = 1954 for AMI and n = 648 for IHD) found that LVEF improved by 
2.92% and reduced infarct size by 2.25%. 32 The authors also concluded that BMSC 
therapy improved clinical outcomes, including all-cause mortality and recurrent 
myocardial Infarction, albeit with differences between AMI and CIHD diagnoses. For 
example, subgroup analysis found that although cell therapy did not reduce risk of 
mortality in AMI patients there was a significant reduction in deaths among patients 
with IHD. 
 
Another major source of heterogeneity in RCTs and therefore subsequent meta-
analyses is associated with biological properties or phenotypes of the cell 
populations used for transplantation. As mentioned above, heterogeneous cell 
populations have been used in clinical trials including unfractionated BMMNC, 
enriched CD34-positive or CD133-positive hematopoietic progenitor cells, peripheral 
blood-derived progenitor cells or bone marrow-derived MSCs. Data derived from the 
REPAIR-AMI trial suggested that basal migratory capacity or SDF-1 (stromal cell-
derived factor-1) -induced migratory capacity of BMSCs may be associated with a 
range of clinical outcomes. 33 Assmus and co-workers found that the more migratory 
cells were associated with improved survival free of cardiac, cardiovascular, 
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unknown death, and re-hospitalization. Robust phenotypic differences in the ability of 
cardiosphere-derived cells from IHD patients to support vessel formation have 
recently been reported. 34 These data suggest that not all patients may be suitable for 
autologous cell transplants. Although current meta-analyses and their associated 
RCTs have yet to consider the phenotypes of the transplanted cells, this is clearly 
one of the major sources of trial heterogeneity and may explain why certain patients 
may benefit from some cell therapy while others do not. 
 
In addition to BMSCs, a meta-analysis of cell therapies from AMI using MSCs has 
recently been published. Wang and colleagues (Table 3) analysed data from 8 
studies containing a total of 449 participants treated with MSCs derived from bone 
marrow, adipose tissue and umbilical cord (allogenic) reporting no increase in LEVF 
in the treatment groups compared to controls. 35 Sub-group analysis found that 
transplantation time, route of delivery and cell dose may affect LVEF in AMI patients 
treated with MSCs. Specifically, the injection of no more than 10 million 
mesenchymal stromal cells, via percutaneous coronary intervention, improved left 
ventricular systolic function when administered within a week of AMI. 
 
Individual patient data and trial sequential analysis 
Prior to undertaking large scale clinical trials (Phase III), meta-analyses remain one 
the most widely used methods to evaluate the benefit of a given intervention. 
However, findings derived from trial meta-analyses can be misleading if pitfalls in 
study designs, risk of reporting bias, and variation across studies are not carefully 
considered. 36, 37 To address some of the limitations and inherent biases associated 
with meta-analysis of RCTs, meta-analyses of individual patient data (IPD) and trial 
sequential analysis (TSA) have recently been applied to AMI trials. 25, 26, 38. In 
addition to summary statistics derived from meta-analyses of multiple trials similar 
analyses can performed using IPD. 39 As its name suggests, IPD meta-analyses use 
prospective data derived from individual patients of all included studies removing the 
reliance on summary statistics for subsequent analyses. Thus, IPD-based meta-
analyses contain transparent controlled data with unique definitions allowing data to 
be reanalysed en masse. Although IPD meta-analyses can help reduce bias 
associated with data analysis and reporting compared with trial meta-analyses, they 
cannot avoid bias or pitfalls associated with trial design. The first IPD-based meta-
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analysis of cell therapy trials for AMI, ACCRUE (meta-Analysis of Cell-based 
CaRdiac stUdiEs), collated data from 12 RCTs containing 1252 individuals (767 
receiving cell therapy and 485 controls) (Table 3). 25 In agreement with the largest 
trials-based meta-analyses described above, the ACCRUE study found that 
intracoronary cell therapy for AMI had no apparent benefit on left ventricular function 
(including measurements of LV function made by MRI) and clinical outcomes in the 
treated group compared to the untreated controls.  
 
Trial sequential analysis (TSA) has been used to resolve some of the inherent 
problems associated with trial meta-analysis such as insufficient statistical power 40, 
41. TSA leverages cumulative data to effectively reduce type I and type II errors and 
can be used to estimate information size (IS), similar to power calculations used in 
individual trials. Fisher and colleagues conducted a TSA on 41 AMI trials that 
included 2739 participants (Table 3). 38  All trials administered BM-derived cells 
(mononuclear cell, BMMSCs, hematopoietic progenitors, circulating progenitor cells). 
An ‘a priori’ threshold of relative risk reduction (RRR) in mortality of 35% was 
established as similar figure was empirically associated to percutaneous coronary 
intervention (PCI) in AMI 42. In summary, cell therapies as currently tested in clinical 
trials do not seem to have a beneficial effect on clinical outcomes when administered 
to AMI patients.  
 
Based upon TSA for AMI, the required IS to detect an effect of 35% RRR in mortality 
in favour of cell treatment was estimated to be 4,055 participants. Similarly, the 
required IS to detect a 35% RRR of re-hospitalization was 3,392 participants. 
However, in practice many more patients will be required to detect smaller effect 
sizes. This study demonstrates that the current AMI RCTs and meta-analyses lack 
sufficient statistical power to detect clinically relevant outcomes explaining the 
inconsistent findings reported in different RCTs and their earlier meta-analyses that 
used shorter follow-up times. 
 
Concluding remarks 
Most meta-analyses reviewed herein seem to agree that the potential beneficial 
effect of cell therapies for HF and AMI is still inconclusive and statistically 
underpowered. In AMI, trial meta-analyses (including TSA) and IPD-based meta-
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analysis have drawn similar conclusions suggesting that cell-based therapies for AMI 
had no apparent clinical benefit. In addition, several recently published large RCTs, 
that have yet to be included in meta-analyses, enrolling patients with ischemic HF 
and AMI, published neutral results regarding changes in LVEF between the cell 
treated and control groups. 5, 43-45 Furthermore, the recently published global position 
paper on cardiovascular regenerative medicine stated that, even if cell-based therapy 
in HF patients proved to be safe, the results are neither positive nor consistent. 46  
 
In addition to the concerns regarding statistical power, the quality of the evidence in 
meta-analyses is confounded by two major sources of variation: (i) pitfalls in trial 
design and (ii) inconsistencies reporting and interpreting trial results. Therefore, there 
is a need for trial standardization and deep data sharing to improve reproducibility. 
To this end, the ACCRUE consortium and guidelines published by the International 
Committee of Medical Journal Editors (ICMJE) recommend data sharing on 
publication of trial results (e.g. sharing of the de-identified IPDs in a confidential form 
within 6 months of the publication). 47, 48 These efforts will hopefully resolve the 
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(No. of trials) Conclusion 
Brunskill et al. 2009 12 21 565 / 526 AMI, CIHD n/r i.m. surgical (4), i.m. 
perc.(1), i.c. (17)* 
only i.m. delivery was effective 
Jiang et al. 2010 13 18 490 / 490 AMI, CIHD n.s. i.m. surgical (2), i.c. (16) cell therapy was effective only in 
patients with AMI  
Donndorf et al. 201114 6 94 / 85 CIHD n.s. i.m. surgical (6) safe and effective 
Zhao et al. 2011 15 10 250 / 207 CIHD n/r i.m. surgical (5), i.c. (6)* cell therapy was effective only 
with CABG but not with PCI 
Wen et al. 2012 16 13 378 / 280 IHD, HF n/r i.m. surgical (4), i.m. 
perc. (6), i.c. (4)* 
cell therapy is more effective in 
patients with IHF  
Kandala et al. 2013 17 10 283 / 236 ICMP n.s. i.m. surgical (7), i.c. (4)* cell more effective with i.m. 
delivery 
Cheng et al. 2013 18 5 135 / 75 Ischemic HF n.s. i.m. surgical (1), i.m. or 
perc. (4) 
6 min walking distance † NYHA 
decrease † 
Fisher et al. 2014 19 23 659 / 478 CIHD, HF sig. i.m. surgical (3), 
i.m.perc. (9), i.c. (12)* 
NYHA class and rehospitalization 
sig. 
Xiao et al. 2014 20 20 453 / 322 CIHD n.s. i.m. surgical (8), i.m. 
perc.(8), i.c. (5)* 
route of delivery, baseline EF and 
type of cells influence significance 
Xu et al. 2014 21 19 440 / 309 CIHD sig. i.m. surgical (7), i.m. 
perc.(7), i.c. (6)* 
safe and effective 
Tian et al. 2014 22 11 272 /220 CIHD sig. i.m. surgical (5), i.m. 
perc. (6) 
more effective if revascularization 
was possible 
Fisher et al. 2015 23 31 626 / 895 HF sig. i.m. surgical (7), i.m. 
perc.(12), i.c. (12) 
sig. for rehospitalization 
Fisher et al. 2016 24 38 1114 / 793 CIHD, HF, 
refractory AP 
sig. i.m. surgical (7), i.m. 
perc (17), i.c. (13) 




Abbreviations: AMI, acute myocardial infarction; AP, angina pectoris; CABG, coronary artery bypass graft; CIHD, chronic ischemic 
heart disease; HF, heart failure; ICMP, ischemic cardiomyopathy; i.c., intracoronary application; i.m., intramyocardial; n/r, not reported; 
n.s., not significant; NYHA, New York Heart Association; perc., percutaneous; * including trials with more than one delivery route; † 




Table 2. Results of the left ventricular function parameters in meta-analyses including patients with ischemic heart failure. 
 
 
HF trials Patient population LVEF difference (%) LVESV difference (mL) LVEDV difference (mL) 
Brunskill et al. 2009 12 CIHD 3.71* n/r n/r 
Jiang et al. 2010 13 AMI and CIHD 2.93* -10.67* 8.61* 
Donndorf et al. 201114 CIHD 5.4* n.s. 9.55 
Zhao et al. 2011 15 CIHD 4.59* -0.36* -0.38* 
Wen et al. 2012 16 IHD and HF 3.83* -16.29 -13.76 
Kandala et al. 2013 17 ICMP 4.48* -20.64* -16.71* 
Cheng et al. 2013 18 Ischemic HF 0.11 (n.s.) n/r n/r 
Fisher et al. 2014 19 CIHD and HF 2.62* -14.64* n.s. 
Xiao et al. 2014 20 CIHD 3.05*-3.35* -11.75* -7.8* 
Xu et al. 2014 21 CIHD 3.54* -8.96* -0.75 
Tian et al. 2014 22 CIHD 4.91* -10.66* -7.82 
Fisher et al. 2015 23 HF 4.02 - 4.66* n/r n/r 
Fisher et al. 2016 24 CIHD, HF, refractory AP -1.6 (n.s.) n/r n/r 
 
 
Abbreviations: AMI, acute myocardial infarction; AP, angina pectoris; CIHD, chronic ischemic heart disease; HF, heart failure; ICMP, 
ischemic cardiomyopathy; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular 
end systolic volume; n/r, not reported; n.s., not significant; * p<0.05. 
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Table 3. Meta-analyses of human randomized clinical trials for patients with acute myocardial infarction. 
 
 
AMI Trials Sample Size 
(No. of studies) 
Follow-up 
(months) 




% change in EF 
(by MRI) 
Hristov et al. 2006 28 482 (5) 4–6 n/r n/r n/r n/r 
Lipinski et al. 2007 49 698 (10) 6 n.s. -4.6 −7.4* n/r 
Martin-Rendon et al. 2008 50 811 (13) 3–6 n.s. -2.47 −4.74* n/r 
Zhang et al. 2009 51 525 (6) 5 n/r -0.15 n/r n/r 
Zhang et al. 2009 52 660 (7) 6 n.s. -0.15 −0.25* n/r 
Bai et al. 2010 53 814 (10) 6 n/r n/r n/r n/r 
Kuswardhani and Soejitno 
2011 54 
906 (10) 4–60 n.s. −3.08* −5.52* n/r 
Takagi and Umemoto 2011 55 877 (15) n/r n/r −0.18* −0.35* nr 
Clifford et al. 2012 29 1765 (33) <12 sig. −3.52* −4.47* 1.78* 
Zimmet et al. 2012 30 1830 (29) 3–6 n.s. −3.39* −3.51* n/r 
Delewi et al. 2013 56 1641 (16) 3–6 n/r n/r n/r 0.16* 
Chen et al. 2013 57 510 (5) n/r n/r -2.29 -4.47 n/r 
Jeong et al. 2013 58 1072 (17) 3–6 n/r -3.46 −4.98* n/r 
de Jong et al. 2014 59 1513 (22) 6 n.s. -2.8 −4.05* 0.13 (n.s.) 
Liu et al. 2014 60 262 (8) 6–24 sig. 0.69 -0.99 n/r 
Fisher et al. 2015 26 2732 (41) 6-60 n.s. n/r n/r 1.05 (n.s.) 
Gyöngyösi et al. 2015 (IPD) 
25 
1275 (12) 12 n.s. 1.2 0.4 n/r 
Cong et al. 2015 61 1318 (17) 12 n.s. -1.69 −3.92* n/r 
Wang et al. 2017 (MSC) 35 449 (8) 1-24 n/r n/r n/r n/r 
Xu et al. 2017 31 2307 (34) 3-61 n.s. n/r n/r n/r 
 
 
Abbreviations: AMI, acute myocardial infarction; EF, ejection fraction; HF, heart failure; IPD, individual patient data; LVEDV, left 
ventricular end diastolic volume; LVESV, left ventricular end systolic volume; MSC, mesenchymal stem cells; MRI, magnetic 
resonance imaging; n/r, not reported; n.s., not significant; * p<0.05. 
